Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Queensland Health
US Department of Justice
McKinsey
Teva
Chubb
Fuji
Covington
Julphar

Generated: April 26, 2018

DrugPatentWatch Database Preview

Gabapentin enacarbil - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for gabapentin enacarbil and what is the scope of gabapentin enacarbil patent protection?

Gabapentin enacarbil
is the generic ingredient in one branded drug marketed by Arbor Pharms Llc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Gabapentin enacarbil has one hundred and forty-seven patent family members in twenty-five countries.

There are twenty-eight drug master file entries for gabapentin enacarbil. Two suppliers are listed for this compound.
Summary for gabapentin enacarbil
Pharmacology for gabapentin enacarbil
Synonyms for gabapentin enacarbil
(1-(((((1RS)-1-((2-methylpropanoyl)oxy)ethoxy)carbonyl)amino)methyl)cyclohexyl)acetic acid
{[(1-Isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-Cyclohexane Acetic Acid
{[(alpha-Isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-Cyclohexane Acetic Acid
{1-[({[1-(isobutyryloxy)ethoxy]carbonyl}amino)methyl]cyclohexyl}acetic acid
1-[[[[1-(2-Methyl-1-oxopropoxy)ethoxy]carbonyl]amino]methyl]cyclohexaneacetic acid
1-{[(alpha-Isobutanovloxyethoxy)carbonyl]aminomethyl}-1-Cyclohexane Acetic Acid
1-{[(alpha-Isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-Cyclohexane Acetic Acid
1-{[(alpha-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexaneacetic acid
2-(1-((((1-(Isobutyryloxy)ethoxy)carbonyl)amino)methyl)cyclohexyl)acetic acid
2-(1-(((1-(isobutyryloxy)ethoxy)carbonyl)methyl)cyclohexyl)acetic acid
2-(1-(((1-(isobutyryloxy)ethoxy)carbonylamino)methyl)cyclohexyl)acetic acid
2-[1-[[[1-[(2-Methylpropanoyl)oxy]ethoxy]carbonylamino]methyl]cyclohexyl]acetic acid
2-[1-[[1-(2-methylpropanoyloxy)ethoxycarbonylamino]methyl]cyclohexyl]acetic acid
296G729
3687AH
478296-72-9
791632-57-0
A20372
AC-27644
ACN-028536
AK170416
AKOS025290727
AN-16701
API0008802
ASP-8825
ASP8825
CHEBI:68840
CHEMBL1628502
CS-1698
Cyclohexaneacetic acid, 1-((((1-(2-methyl-1-oxopropoxy)ethoxy)carbonyl)amino)methyl)-
Cyclohexaneacetic acid,1-[[[[1-(2-methyl-1-oxopropoxy)ethoxy]carbonyl]amino]methyl]-
D05KBU
D09539
DB08872
FT-0753836
Gabapentin enacarbil (JAN/USAN/INN)
Gabapentin enacarbil [USAN:INN]
Gabapentin-XP
gabapentina enacarbilo
gabapentine enacarbil
Gabapentinenacarbil
gabapentinum enacarbilum
GSK 1838262
GSK-1838262
GSK1838262
GTPL7560
Horizant
Horizant (TN)
Horizant, Regnite
Horizant|||Regnite|||XP 13512
HY-16216
MFCD09954124
OR068058
OR272863
PB32822
Q-1947
Regnite
SCHEMBL25455
Solzira
TZDUHAJSIBHXDL-UHFFFAOYSA-N
XP 13512
XP-053
XP-13512
XP13512

US Patents and Regulatory Information for gabapentin enacarbil

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-001 Apr 6, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-002 Dec 13, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-001 Apr 6, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-001 Apr 6, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for gabapentin enacarbil

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,238,616 Prodrugs of gaba analogs, compositions and uses thereof ➤ Sign Up
8,168,623 Prodrugs of GABA analogs, compositions and uses thereof ➤ Sign Up
7,186,855 Prodrugs of GABA analogs, compositions and uses thereof ➤ Sign Up
7,232,924 Methods for synthesis of acyloxyalkyl derivatives of GABA analogs ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Covington
Mallinckrodt
Cantor Fitzgerald
Fish and Richardson
Fuji
Johnson and Johnson
Accenture
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.